Capricor Deramiocel Phase 3 HOPE-3 Meets Primary in Duchenne Muscular Dystrophy

Phase 3 HOPE-3 met PUL v2.0 primary endpoint, with reduced cardiac LGE progression (p=0.022) and improved LVEF (p=0.017). PDUFA date set for August 22, 2026.